MetaLinear is a start-up biotechnology company founded in 2017, focused on the identification and validation of new drug targets for difficult to treat bacterial infections. The new investment was secured from the BioCity Group Ltd, who manage the Alderley Park Ventures (APV) fund and Catapult Ventures, who manage the Greater Manchester and Cheshire (GM&C) Life Sciences Fund. Both funds look to back innovative, high-technology companies providing much needed early stage finance.
Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
Even when the flu vaccine doesn't prevent disease, it can ease some of the consequences, researchers said here.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.